Theralase Announces Further Changes to Board of Directors



    TORONTO, June 26 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today
announced that Frank Ricciuti has been appointed to the Company's Board of
Directors. In addition, H. Dan Routledge has resigned from the Board of
Directors.
    Mr. Ricciuti is currently the President of Efjay Consulting Ltd., a
private financial and corporate advisory management company. During his long
business career, Mr. Ricciuti has served on the boards of numerous public and
private companies. Mr. Ricciuti was also a senior executive with BP Canada
Inc., Canterra Energy, Merrill Lynch, Research Capital and Scotia Capital. Mr.
Ricciuti earned a diploma in Engineering Technology from Ryerson University, a
Bachelor of Science degree in Mechanical Engineering from Michigan Technology
University and an MBA from York University.
    "We are pleased to welcome Frank to our Board," said Donald Moore,
Chairman of Theralase's Board of Directors. "Theralase can benefit from
Frank's 30 years of industry and director experience, in particular, his
knowledge and experience in the capital markets and technology sectors."

    Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors: firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions, including arthritis; secondly, to bio-stimulate and accelerate
wound care and healing, including bone fracture regeneration; and thirdly,
combining photodynamic compounds with super-pulsed, biofeedback laser
technology to attack specifically targeted cancer, bacteria, viruses and fat
cells.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this
    release.





For further information:

For further information: Roger White, President & CEO, Toll Free:
1-866-THE-LASE (843-5273), Phone: (416) 447-8455, e-mail:
rwhite@theralase.com; Vanessa Beresford, The Equicom Group, Phone: (416) 815
0700 ext 227, e-mail: vberesford@equicomgroup.com

Organization Profile

THERALASE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890